Spain's Almirall Pledges $400M For Skin Drug Co. Aqua

Law360, New York (December 17, 2013, 1:10 PM EST) -- Spanish drugmaker Almirall SA said Tuesday it would pay roughly $400 million for private equity-backed prescription skin-care company Aqua Pharmaceuticals LLC, a move that will diversify its holdings and allow it to crack into the biggest dermatology market in the world.

Pennsylvania-based Aqua, majority-owned by RoundTable Healthcare Partners, manufactures treatments for acne and other skin conditions under the popular Monodox and Cordran names. The company is expected to bring in $127 million in sales for this year, fueled by its presence in its home market, a...
To view the full article, register now.